ES2437321T3 - Composición para tratar un trastorno de la piel en un ser humano - Google Patents

Composición para tratar un trastorno de la piel en un ser humano Download PDF

Info

Publication number
ES2437321T3
ES2437321T3 ES08020820.0T ES08020820T ES2437321T3 ES 2437321 T3 ES2437321 T3 ES 2437321T3 ES 08020820 T ES08020820 T ES 08020820T ES 2437321 T3 ES2437321 T3 ES 2437321T3
Authority
ES
Spain
Prior art keywords
composition
gel
tretinoin
water
clindamycin phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES08020820.0T
Other languages
English (en)
Spanish (es)
Inventor
Gordon J. Dow
Robert W. Lathrop
Debra A. Dow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Pharmaceutical Sciences Inc
Original Assignee
Dow Pharmaceutical Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24535786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2437321(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dow Pharmaceutical Sciences Inc filed Critical Dow Pharmaceutical Sciences Inc
Application granted granted Critical
Publication of ES2437321T3 publication Critical patent/ES2437321T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES08020820.0T 2000-08-03 2001-07-24 Composición para tratar un trastorno de la piel en un ser humano Expired - Lifetime ES2437321T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US632508 1984-07-19
US09/632,508 US6387383B1 (en) 2000-08-03 2000-08-03 Topical low-viscosity gel composition

Publications (1)

Publication Number Publication Date
ES2437321T3 true ES2437321T3 (es) 2014-01-10

Family

ID=24535786

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08020820.0T Expired - Lifetime ES2437321T3 (es) 2000-08-03 2001-07-24 Composición para tratar un trastorno de la piel en un ser humano
ES01957238T Expired - Lifetime ES2326955T3 (es) 2000-08-03 2001-07-24 Sistemas topicos de liberacion de gel para el tratamiento de trastornos de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01957238T Expired - Lifetime ES2326955T3 (es) 2000-08-03 2001-07-24 Sistemas topicos de liberacion de gel para el tratamiento de trastornos de la piel.

Country Status (24)

Country Link
US (2) US6387383B1 (enEXAMPLES)
EP (2) EP2052714B1 (enEXAMPLES)
JP (1) JP4988129B2 (enEXAMPLES)
KR (2) KR100840169B1 (enEXAMPLES)
CN (2) CN101305982B (enEXAMPLES)
AR (1) AR030093A1 (enEXAMPLES)
AT (1) ATE429922T1 (enEXAMPLES)
AU (2) AU7900201A (enEXAMPLES)
BE (1) BE2013C060I2 (enEXAMPLES)
BR (1) BR0113247A (enEXAMPLES)
CA (1) CA2417646C (enEXAMPLES)
CY (3) CY1109189T1 (enEXAMPLES)
DE (1) DE60138549D1 (enEXAMPLES)
DK (2) DK2052714T3 (enEXAMPLES)
ES (2) ES2437321T3 (enEXAMPLES)
FR (1) FR14C0053I1 (enEXAMPLES)
LU (1) LU92401I2 (enEXAMPLES)
MX (1) MXPA03001006A (enEXAMPLES)
PL (1) PL213237B1 (enEXAMPLES)
PT (2) PT2052714E (enEXAMPLES)
RU (1) RU2251410C2 (enEXAMPLES)
SI (2) SI2052714T1 (enEXAMPLES)
WO (1) WO2002011683A1 (enEXAMPLES)
ZA (1) ZA200301037B (enEXAMPLES)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100638150B1 (ko) 1998-12-23 2006-10-26 이데아 악티엔게젤샤프트 생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
JP2004532853A (ja) 2001-05-09 2004-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 酒さを治療する目的での組成物の使用
US7368122B1 (en) * 2002-03-08 2008-05-06 Dow Pharmaceutical Sciences Skin cream
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
EP2266533A3 (en) * 2002-06-25 2011-12-14 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
US20040171561A1 (en) * 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
US20040167223A1 (en) * 2002-09-03 2004-08-26 Popp Karl F. Topical antibacterial formulations
US6906014B2 (en) * 2002-09-10 2005-06-14 Permatex, Inc. Stabilized topical composition
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US7208485B2 (en) * 2003-01-13 2007-04-24 Chemagis Ltd. Crystalline forms of halobetasol propionate
RS20050557A (en) 2003-01-24 2007-09-21 Connetics Australia Pty Ltd., Clindamycin phosphate foam
US20060135607A1 (en) * 2003-02-07 2006-06-22 Mochida Pharmaceutical Co., Ltd. Drug for improving prognosis for subarachnoid hemorrhage
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
MXPA06001669A (es) 2003-08-12 2006-04-28 3M Innovative Properties Co Compuestos que contienen imidazo-oxima sustituidos.
CA2537080A1 (en) * 2003-08-21 2005-03-31 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US7897597B2 (en) 2003-08-27 2011-03-01 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2005023190A2 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US20050095245A1 (en) * 2003-09-19 2005-05-05 Riley Thomas C. Pharmaceutical delivery system
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EP1669379B1 (en) * 2003-09-23 2007-11-14 Akciju Sabiedriba "Olainfarm" 3,5-dimethyl-1-adamantyl-ammonium polymeric salts and the use thereof in the form of antiviral agents
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
BRPI0414856A (pt) 2003-10-03 2006-11-21 3M Innovative Properties Co imidazoquinolinas alcóxi-substituìdas
US20050095215A1 (en) * 2003-11-03 2005-05-05 Popp Karl F. Antimicrobial shampoo compositions
US8598192B2 (en) * 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
WO2005048933A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
KR101249639B1 (ko) * 2003-12-30 2013-04-01 오클루스 이노바티브 사이언시즈 인코포레이티드 산화환원전위 수용액, 그의 제조방법 및 이를 사용하는방법
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US20050255131A1 (en) * 2004-05-11 2005-11-17 Mohan Vishnupad Clindamycin compositions and delivery system therefor
US20060014834A1 (en) * 2004-05-11 2006-01-19 Mohan Vishnupad Retinoid solutions and formulations made therefrom
US7662855B2 (en) * 2004-05-11 2010-02-16 Imaginative Research Associates, Inc. Retinoid solutions and formulations made therefrom
BRPI0511519A (pt) 2004-05-25 2007-12-26 Sansrosa Pharmaceutical Dev In método para tratar ou prevenir um distúrbio inflamatório da pele e os sintomas associados com ele, composição tópica adequada para tratar ou evitar os sintomas de um distúrbio inflamatório dermatológico, e, embalagem para uma composição tópica
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
ITMI20041376A1 (it) * 2004-07-09 2004-10-09 Uni Campus Bio Medico Di Roma Metodo di preparazione di un sistema polimerico biocompatibile per il rilascio farmacologico in uso topico e impieghi di detto sistema
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
DE602005021238D1 (de) * 2004-11-09 2010-06-24 Imaginative Res Associates Inc Retinoidlösungen und formulierungen daraus
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
ES2392648T3 (es) 2004-12-30 2012-12-12 3M Innovative Properties Company Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
EP1831226B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Chiral tetracyclic compounds inducing interferon biosynthesis
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
JP2008540534A (ja) * 2005-05-09 2008-11-20 ドラッグテック コーポレイション 放出調節薬学組成物
BRPI0611134A2 (pt) 2005-06-03 2010-08-17 Acrux Dds Pty Ltd método e composição para liberação transdérmica de fármaco
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
JPWO2007023729A1 (ja) * 2005-08-23 2009-02-26 日産化学工業株式会社 徐放性製剤
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070224226A1 (en) * 2006-01-05 2007-09-27 Drugtech Corporation Composition and method of use thereof
KR20080083190A (ko) * 2006-01-05 2008-09-16 드러그테크 코포레이션 외음질 표면에 생체접착을 위한 약물 전달 시스템
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
US20090053290A1 (en) * 2006-03-08 2009-02-26 Sand Bruce J Transdermal drug delivery compositions and topical compositions for application on the skin
ES2582654T3 (es) 2006-03-31 2016-09-14 Stiefel Research Australia Pty Ltd Gel en suspensión espumable
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
RU2309738C1 (ru) * 2006-08-28 2007-11-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав с противовоспалительным и обезболивающим действием и способ его получения
CN104606126A (zh) 2006-10-17 2015-05-13 纽沃研究股份有限公司 双氯芬酸凝胶
AU2008210557B2 (en) 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
US20080287373A1 (en) * 2007-05-17 2008-11-20 Popp Karl F Topical skin treating kits
US20080312245A1 (en) * 2007-06-12 2008-12-18 Longyan Xiao Methods and compositions for treating acne and other infectious diseases
AU2008298592A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
US20090098191A1 (en) * 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
WO2009051839A1 (en) * 2007-10-18 2009-04-23 Medicis Pharmaceutical Corporation Aqueous retinoid and benzoyl peroxide gel
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
EP2214678A2 (en) * 2007-11-13 2010-08-11 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
WO2009082452A1 (en) 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment
US20090176719A1 (en) * 2008-01-07 2009-07-09 Liolabs Llc Compositions and methods for treating perioral dermatitis
RU2497515C2 (ru) * 2008-03-17 2013-11-10 Гленмарк Фармасьютикалс Лимитед Состав для топического применения, содержащий микросферы адапалена и клиндамицин
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
RU2490035C2 (ru) * 2008-05-16 2013-08-20 Галдерма Ресерч Энд Девелопмент Схема лечения заболеваний, связанных с акне
CN102056481A (zh) 2008-06-05 2011-05-11 陶氏制药科学公司 包含低浓度的在水和水混溶性有机溶剂中的悬浮液形式的过氧苯甲酰的局部药物制剂
MX2010013946A (es) * 2008-06-24 2011-02-15 Intervet Int Bv Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en ganado.
US20100105750A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
DK2473161T3 (en) 2009-08-31 2017-09-11 Dr Reddys Laboratories Ltd TOPICAL FORMULATIONS INCLUDING A STEROID
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2792649A1 (en) 2010-03-26 2011-09-29 Michael Graeber Improved methods and compositions for safe and effective treatment of telangiectasia
ES2627405T3 (es) 2010-03-26 2017-07-28 Galderma Research & Development Composiciones que comprenden brimonidina para el tratamiento del eritema
AU2011273509A1 (en) 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US8911713B2 (en) 2010-06-30 2014-12-16 Galderma Research & Development Method for preventing or treating skin tumor
SI2444068T1 (sl) 2010-10-21 2014-11-28 Galderma S.A. Brimodin gel sestavek
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
WO2013019974A1 (en) 2011-08-02 2013-02-07 Medicis Pharmaceutical Corporation Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea
PH12014500785A1 (en) 2011-10-19 2014-05-12 Galderma Sa Method for treating capillary hemangiomas
JP2014530846A (ja) 2011-10-19 2014-11-20 ガルデルマ ソシエテ アノニム ホスホジエステラーゼ５型阻害薬の全身使用に伴う顔面潮紅の軽減方法
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
RU2548714C2 (ru) * 2012-05-03 2015-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения угревой болезни и способ ее получения
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
RU2530644C2 (ru) * 2012-11-01 2014-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Противоугревая фармацевтическая композиция и способ ее получения
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
WO2015044788A1 (en) 2013-09-26 2015-04-02 Galderma S.A. Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring
US10201481B2 (en) * 2014-03-07 2019-02-12 The Procter & Gamble Company Personal care compositions and methods of making same
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9012402B1 (en) * 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
CN104473865A (zh) * 2014-11-17 2015-04-01 重庆华邦制药有限公司 地奈德凝胶剂及其制备方法
KR20170110083A (ko) 2014-12-23 2017-10-10 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 경피 투여를 위한 방법 및 제형
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
RS60672B1 (sr) 2015-06-18 2020-09-30 Bausch Health Ireland Ltd Topikalne kompozicije koje sadrže kortikosteroide i retinoid za lečenje psorijaze
AU2016294504B2 (en) 2015-07-13 2019-07-18 Dr. Reddy's Laboratories, Ltd. Topical retinoid compositions
CN106474048A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的地奈德凝胶制剂
CN106474059A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种质量更加稳定的地奈德洗剂
CN106474047A (zh) * 2015-08-27 2017-03-08 重庆华邦制药有限公司 一种对光稳定的地奈德制剂
EP3436431A1 (en) 2016-03-28 2019-02-06 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
WO2018213310A1 (en) 2017-05-15 2018-11-22 Cornell University Device and system for repairing intervertebral disc herniation and methods of use
US10779525B2 (en) 2018-01-16 2020-09-22 Zin Research LLC Treatment compound and method of application for hoof or foot disease in animals
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
US20200138822A1 (en) * 2018-11-06 2020-05-07 Tim COTE Topical compositions comprising pentoxifylline and methods of treatment using the same
FR3090385B1 (fr) * 2018-12-21 2021-01-08 Pf Medicament Composition émolliente sous forme d’émulsion
CN111743853A (zh) * 2019-03-29 2020-10-09 天津金耀集团有限公司 一种近中性丁酸氢化可的松的外用药物组合物
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
AU2021410145A1 (en) * 2020-12-24 2023-07-27 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition for topical administration containing epinastine or salt thereof
US20220202841A1 (en) * 2020-12-24 2022-06-30 Erine A. Kupetsky Dermatological formulations for treatment of dermatitis
MX2024008192A (es) * 2021-12-28 2024-09-10 Arcutis Biotherapeutics Inc Espumas en aerosol de roflumilast topico.
EP4525862A1 (en) 2022-05-20 2025-03-26 Dermbiont, Inc. Compositions and formulations for use of a pk inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3969516A (en) * 1974-12-19 1976-07-13 Nelson Research & Development Company Composition and method for treatment of acne
US4497794A (en) 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US4361584A (en) 1977-10-07 1982-11-30 A.H.C. Pharmacal, Inc. Composition and method for the treatment of acne
US4247547A (en) 1979-03-19 1981-01-27 Johnson & Johnson Tretinoin in a gel vehicle for acne treatment
US4387107A (en) 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4692329A (en) 1980-12-08 1987-09-08 William H. Rorer, Inc. Erythromycin/benzoyl peroxide antiacne compositions
LU83173A1 (fr) 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
US4514385A (en) 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
CH643138A5 (de) * 1983-08-29 1984-05-30 Mepha Ag Indomethacin enthaltende, gelartige salbe.
LU85111A1 (fr) 1983-12-01 1985-09-12 Oreal Composition anti-acnetique a base de peroxyde de benzoyle et d'au moins un filtre solaire
US4670254A (en) * 1983-12-09 1987-06-02 Toko Yakuhin Industry Co., Ltd. Gel preparations for topical application of diclofenac sodium
US5446028A (en) 1985-12-12 1995-08-29 Dermik Laboratories, Inc. Anti-acne method and composition
FR2604357B1 (fr) 1986-09-30 1988-12-02 Oreal Composition pharmaceutique et cosmetique anti-acneique
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
EP0305380B1 (en) * 1987-03-20 1991-09-25 Galderma S.A. Novel topical metronidazole formulations
MY105521A (en) * 1989-04-17 1994-10-31 Healthpoint Ltd Moisturizing vehicle for topical application of vitamin a acid.
US5721275A (en) 1989-06-07 1998-02-24 Bazzano; Gail S. Slow release vehicles for minimizing skin irritancy of topical compositions
US5122519A (en) * 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
GB9021320D0 (en) 1990-10-01 1990-11-14 Diomed Dev Ltd Compositions for topical application
US5380528A (en) 1990-11-30 1995-01-10 Richardson-Vicks Inc. Silicone containing skin care compositions having improved oil control
DK0608353T3 (da) * 1991-10-16 1996-07-01 Richardson Vicks Inc Vandig, kosmetisk gel med lav pH-værdi og indeholdende ikke-ioniske polyacrylamidderivater
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
US5549914A (en) * 1992-12-14 1996-08-27 Sween Corporation Heat stable wound care gel
DK0706370T4 (da) 1993-07-01 2005-04-18 Yamanouchi Europ Bv Anvendelse af nonioniske overfladeaktive stoffer i stabile topiske retinoidsammensætninger
US5482710A (en) 1993-07-30 1996-01-09 Chesebrough-Pond'usa Co., Division Of Conopco, Inc. Cosmetic composition for treatment of pimples and redness
US5382432A (en) 1993-11-15 1995-01-17 Elizabeth Arden Company, Division Of Conopco, Inc. Cosmetic method for treatment of skin
US5466446A (en) 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
ATE208212T1 (de) * 1994-03-21 2001-11-15 Thomsen John Brown Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
US5538732A (en) 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
US5451405A (en) 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
US5445823A (en) 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5750122A (en) 1996-01-16 1998-05-12 The Procter & Gamble Company Compositions for treating hair or skin
JP3193617B2 (ja) * 1996-01-29 2001-07-30 カネボウ株式会社 清涼感付与剤および人体用組成物
US5891451A (en) 1996-06-25 1999-04-06 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters
RU2119329C1 (ru) * 1996-06-26 1998-09-27 Акционерное общество открытого типа "Щелковское предприятие Агрохим" Основа для репеллентных кремов
FR2753626B1 (fr) * 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
JPH1179948A (ja) * 1997-09-12 1999-03-23 Noevir Co Ltd 養毛剤及び毛髪用化粧料、並びに皮脂分泌抑制用皮膚外用剤
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition

Also Published As

Publication number Publication date
EP1304992A1 (en) 2003-05-02
PL213237B1 (pl) 2013-01-31
CN101305982B (zh) 2011-12-14
EP1304992B1 (en) 2009-04-29
CY2014005I2 (el) 2015-12-09
MXPA03001006A (es) 2005-02-25
CY1114646T1 (el) 2016-12-14
CY2014005I1 (el) 2014-07-02
CN1460013A (zh) 2003-12-03
BR0113247A (pt) 2003-06-24
FR14C0053I1 (fr) 2014-08-08
US6517847B2 (en) 2003-02-11
AU7900201A (en) 2002-02-18
KR20030057526A (ko) 2003-07-04
AR030093A1 (es) 2003-08-13
CA2417646A1 (en) 2002-02-14
CN101305982A (zh) 2008-11-19
EP2052714A1 (en) 2009-04-29
SI2052714T1 (sl) 2013-11-29
ES2326955T3 (es) 2009-10-22
PT2052714E (pt) 2013-10-17
US6387383B1 (en) 2002-05-14
EP2052714B1 (en) 2013-09-04
SI1304992T1 (sl) 2009-10-31
EP1304992A4 (en) 2006-11-02
ZA200301037B (en) 2004-02-09
LU92401I2 (fr) 2014-05-19
PT1304992E (pt) 2009-07-20
PL360589A1 (pl) 2004-09-06
BE2013C060I2 (enEXAMPLES) 2020-12-15
HK1125847A1 (en) 2009-08-21
KR20080036246A (ko) 2008-04-25
RU2251410C2 (ru) 2005-05-10
JP4988129B2 (ja) 2012-08-01
ATE429922T1 (de) 2009-05-15
DK1304992T3 (da) 2009-08-10
JP2004505900A (ja) 2004-02-26
AU2001279002B2 (en) 2006-04-27
DK2052714T3 (da) 2013-10-14
CA2417646C (en) 2010-05-04
DE60138549D1 (de) 2009-06-10
CY1109189T1 (el) 2014-07-02
KR100840169B1 (ko) 2008-06-23
WO2002011683A1 (en) 2002-02-14
US20020176891A1 (en) 2002-11-28
CN1460013B (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
ES2437321T3 (es) Composición para tratar un trastorno de la piel en un ser humano
AU2001279002A1 (en) Topical gel delivery system
JP6277124B2 (ja) 局所用組成物
US7368122B1 (en) Skin cream
CN113662913B (zh) 局部组合物及其使用方法
ES2279391T3 (es) Composicion farmaceutica topica de tintura verde a base de metronidazol.
Lein et al. Dermal
Bharat et al. A review: Novel advances in semisolid dosage forms & patented technology in semisolid dosage forms
Sabri et al. An investigation release and rheological properties of miconazole nitrate from Emulgel
Chandel et al. An overview on emulgel
Srivastava Excipients for semisolid formulations
Ansari et al. Advances in semisolid dosage form
CN106456781B (zh) 用于指甲治疗的水醇系统
HK1125847B (en) Topical gel delivery system
RU2548714C2 (ru) Фармацевтическая композиция для лечения угревой болезни и способ ее получения
JP7512365B2 (ja) 油性外用液
Mashori et al. GELS as Pharmaceutical Form in Hospital Galenic Practice: Chemico-physical and Pharmaceutical Aspects